Rank,Term name,P-value,Z-score,Combined score,Overlapping genes,Adjusted p-value,Old p-value,Old adjusted p-value,gene count
1,The Overlap Between Signal Transduction Pathways that Contribute to a Range of LMNA Laminopathies WP4879,3.439560767989784e-05,7.5225225225225225,77.31333970594598,"['CEBPB', 'MAOB', 'CEBPD', 'WNT7B', 'HMGA2', 'TNFRSF11B', 'HES1', 'HES5']",0.010628242773088433,0,0,8
2,Differentiation Pathway WP2848,0.00011517789520441145,13.290220104379397,120.52944084998644,"['NT5E', 'EGF', 'HGF', 'WNT7B', 'VEGFA']",0.01779498480908157,0,0,5
3,The influence of laminopathies on Wnt signaling WP4844,0.0008789321982011875,7.8472780906409225,55.219748428095265,"['CEBPB', 'CEBPD', 'HMGA2', 'HES1', 'HES5']",0.08878398921387394,0,0,5
4,Globo Sphingolipid Metabolism WP1424,0.0011493073037394685,10.600904977375565,71.75324157035556,"['ST6GAL1', 'ST6GAL2', 'FUT2', 'A4GALT']",0.08878398921387394,0,0,4
5,Structural Pathway of Interleukin 1 (IL-1) WP2637,0.0018352101236451914,5.186538461538461,32.67828501585148,"['IL1R1', 'IRAK2', 'IRF7', 'TAB2', 'IL1RAP', 'MAP3K14']",0.11341598564127282,0,0,6
6,Hypertrophy Model WP516,0.002371841363178867,14.729786342689568,89.02813487812745,"['IL1R1', 'IL18', 'VEGFA']",0.12214983020371166,0,0,3
7,Endochondral Ossification with Skeletal Dysplasias WP4808,0.004231031357399152,5.226602306248324,28.564999215773106,"['SERPINH1', 'COL10A1', 'SLC38A2', 'DDR2', 'VEGFA']",0.15055079277415465,0,0,5
8,Endochondral Ossification WP474,0.004231031357399152,5.226602306248324,28.564999215773106,"['SERPINH1', 'COL10A1', 'SLC38A2', 'DDR2', 'VEGFA']",0.15055079277415465,0,0,5
9,Signal transduction through IL1R WP4496,0.004384974546820038,6.886470588235294,37.390584150702324,"['IRAK2', 'IL1R1', 'IL1RAP', 'MAP3K14']",0.15055079277415465,0,0,4
10,Transcription factor regulation in adipogenesis WP3599,0.0053049453130565765,10.308211143695015,54.005912032811565,"['CEBPB', 'CEBPD', 'IRS2']",0.1639228101734482,0,0,3
11,Genotoxicity pathway WP4286,0.005893257623101072,4.789823008849558,24.590694388309352,"['ARRDC4', 'ACTA2', 'ITPKC', 'CEBPD', 'PCDH8']",0.16554696413983921,0,0,5
12,IL17 signaling pathway WP2112,0.0067727724130789225,5.986700767263427,29.902640965428148,"['CEBPB', 'CEBPD', 'MAP3K14', 'IL17RB']",0.17439888963678224,0,0,4
13,Apoptosis Modulation and Signaling WP1772,0.007621450341216319,3.7671866594943517,18.37177293212088,"['IL1R1', 'BAG3', 'FAS', 'TNFRSF11B', 'MAP3K14', 'HSPA1A']",0.18115601195660327,0,0,6
14,Vitamin D Receptor Pathway WP2877,0.008896225277629073,3.6343818125194645,17.162016913047346,"['CEACAM1', 'BCL6', 'S100A6', 'PRKCQ', 'TNFRSF11B', 'ATP2C2']",0.19104702454140754,0,0,6
15,Adipogenesis WP236,0.009350590301027334,3.184327658909886,14.878184445439924,"['SOCS3', 'CEBPB', 'KLF6', 'CEBPD', 'ID3', 'FAS', 'IRS2']",0.19104702454140754,0,0,7
16,Complement system WP2806,0.009892402565250875,5.294570135746606,24.439673451269552,"['C1R', 'PROS1', 'SERPING1', 'LAMB1']",0.19104702454140754,0,0,4
17,Transcriptional cascade regulating adipogenesis WP4211,0.011258359236941469,17.13888888888889,76.89609956364617,"['CEBPB', 'CEBPD']",0.19902753857209912,0,0,2
18,Complement and Coagulation Cascades WP558,0.011593837198374705,7.360494344365312,32.807795993683975,"['C1R', 'PROS1', 'SERPING1']",0.19902753857209912,0,0,3
19,IL-1 signaling pathway WP195,0.01247130331313395,3.9162644140520246,17.170176011847506,"['IL1R1', 'IRAK2', 'TAB2', 'IL1RAP', 'MAP3K14']",0.20282277493465214,0,0,5
20,Spinal Cord Injury WP2431,0.013628043676345897,3.286559594251902,14.117829444499428,"['LGALS3', 'ZFP36', 'VCAN', 'IL1R1', 'PLA2G5', 'GFAP']",0.2105532747995441,0,0,6
21,Gene regulatory network modelling somitogenesis  WP2854,0.015466772167556413,13.709941520467837,57.15758644362325,"['HES1', 'TBX6']",0.21723784544431507,0,0,2
22,MicroRNA for Targeting Cancer Growth and Vascularization in Glioblastoma WP3593,0.015466772167556413,13.709941520467837,57.15758644362325,"['HES1', 'VEGFA']",0.21723784544431507,0,0,2
23,MAPK Signaling Pathway WP382,0.01888799486622007,2.155545375884359,8.55585268004552,"['MRAS', 'IL1R1', 'DUSP1', 'EGF', 'FAS', 'HSPB1', 'TAB2', 'MAP3K6', 'MAP3K14', 'HSPA1B', 'HSPA1A']",0.25375610494182615,0,0,11
24,Type I collagen synthesis in the context of Osteogenesis imperfecta WP4786,0.023648554939070504,5.421206976385244,20.299456178433456,"['SERPINH1', 'P3H2', 'TNFRSF11B']",0.28179677105025075,0,0,3
25,Lung fibrosis WP3624,0.023648554939070504,5.421206976385244,20.299456178433456,"['CEBPB', 'EGF', 'HGF']",0.28179677105025075,0,0,3
26,Neural Crest Differentiation WP2064,0.024389989126693993,3.248733789725608,12.064440989502128,"['HES1', 'TBX6', 'ETS1', 'HES5', 'GFAP']",0.28179677105025075,0,0,5
27,Dopamine metabolism WP2436,0.02553498248999036,9.791144527986633,35.91103859817293,"['NQO1', 'MAOB']",0.28179677105025075,0,0,2
28,IL1 and megakaryocytes in obesity WP2865,0.02553498248999036,9.791144527986633,35.91103859817293,"['IL1R1', 'IL18']",0.28179677105025075,0,0,2
29,Exercise-induced Circadian Regulation WP410,0.03099444552336614,3.6188854489164086,12.571817215633278,"['CEBPB', 'RBPMS', 'TAB2', 'ETV6']",0.33025116092138407,0,0,4
30,Apoptosis-related network due to altered Notch3 in ovarian cancer WP2864,0.033432018680916165,3.52579185520362,11.981491127571116,"['SOCS3', 'NQO1', 'HSPB1', 'ETS1']",0.3443497924134365,0,0,4
31,Differentiation of white and brown adipocyte WP2895,0.03757755629848965,7.614035087719298,24.984301196006566,"['CEBPB', 'SMAD9']",0.3518625726131303,0,0,2
32,GDNF/RET signaling axis WP4830,0.03757755629848965,7.614035087719298,24.984301196006566,"['IFT27', 'SPRY1']",0.3518625726131303,0,0,2
33,Leptin Insulin Overlap WP3935,0.03757755629848965,7.614035087719298,24.984301196006566,"['SOCS3', 'IRS2']",0.3518625726131303,0,0,2
34,Cysteine and methionine catabolism WP4504,0.04425949331341045,6.852046783625731,21.362526165228346,"['BHMT', 'SQOR']",0.39216190546313184,0,0,2
35,Bladder cancer WP2828,0.04441963330488548,4.118005865102639,12.823773825739574,"['EGF', 'DAPK2', 'VEGFA']",0.39216190546313184,0,0,3
36,"Non-genomic actions of 1,25 dihydroxyvitamin D3 WP4341",0.04725524754595039,3.1237967914438505,9.534426239596286,"['PLCE1', 'PRKCQ', 'ETS1', 'IFI44L']",0.4056075414360742,0,0,4
37,Extracellular vesicles in the crosstalk of cardiac cells WP4300,0.05134215009482467,6.228601807549176,18.49423371760828,"['EGF', 'HSPB1']",0.4174927468237059,0,0,2
38,Phytochemical activity on NRF2 transcriptional activation WP3,0.05134215009482467,6.228601807549176,18.49423371760828,"['NQO1', 'CEBPB']",0.4174927468237059,0,0,2
39,Aryl Hydrocarbon Receptor Netpath WP2586,0.05282694436795686,3.812316715542522,11.211009035087939,"['NQO1', 'KLF6', 'VEGFA']",0.4185519438384274,0,0,3
40,Control of immune tolerance by vasoactive intestinal peptide WP4484,0.05618602045424288,34.1865889212828,98.42617397275903,['FAS'],0.4340370080090262,0,0,1
41,NAD+ metabolism WP3644,0.058797404906526005,5.70906432748538,16.17753328807612,"['NT5E', 'CD38']",0.443131661368696,0,0,2
42,Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways WP706,0.0609447702830521,2.2449832775919734,6.280985545905696,"['CEBPB', 'CHRNA4', 'PAH', 'HES1', 'HES5', 'VEGFA']",0.44837938136816896,0,0,6
43,Oncostatin M Signaling Pathway WP2374,0.06379402177190356,2.803841536614646,7.716440504604226,"['SOCS3', 'CEBPB', 'OSMR', 'VEGFA']",0.45842680761670235,0,0,4
44,MFAP5 effect on permeability and motility of endothelial cells via cytoskeleton rearrangement WP4560,0.0665984052527732,5.269455690508322,14.275348813992766,"['ACTN1', 'PRKCQ']",0.46770243688879365,0,0,2
45,Nuclear Receptors Meta-Pathway WP2882,0.0744479114572131,1.8048420687261368,4.68835805858033,"['NQO1', 'HGF', 'SPINK13', 'IRS2', 'HES1', 'SPRY1', 'SLC5A3', 'HSPA1A', 'CYP3A7']",0.5019202453054198,0,0,9
46,Apoptosis Modulation by HSP70 WP384,0.07471951871860617,4.892648287385129,12.691597793546247,"['FAS', 'HSPA1A']",0.5019202453054198,0,0,2
47,Benzene metabolism WP3891,0.0830872861952239,17.091836734693878,42.52215817653868,['NQO1'],0.5137822449376467,0,0,1
48,Hypothetical Craniofacial Development Pathway WP3655,0.0830872861952239,17.091836734693878,42.52215817653868,['ARHGAP29'],0.5137822449376467,0,0,1
49,SARS-CoV-2 altering angiogenesis via NRP1 WP5065,0.0830872861952239,17.091836734693878,42.52215817653868,['VEGFA'],0.5137822449376467,0,0,1
50,Monoamine Transport WP727,0.08313628558861598,4.5660818713450295,11.3570968243095,"['IL1R1', 'TNFRSF11B']",0.5137822449376467,0,0,2
51,White fat cell differentiation WP4149,0.09182537311611777,4.2803362573099415,10.220872088094241,"['CEBPB', 'CEBPD']",0.5374511421687308,0,0,2
52,Ovarian infertility WP34,0.09182537311611777,4.2803362573099415,10.220872088094241,"['CEBPB', 'SYNE2']",0.5374511421687308,0,0,2
53,TYROBP causal network in microglia WP3945,0.10076453150083567,4.0282077743378055,9.244611384770696,"['IL18', 'IL13RA1']",0.5374511421687308,0,0,2
54,Mammary gland development pathway - Pregnancy and lactation (Stage 3 of 4) WP2817,0.10076453150083567,4.0282077743378055,9.244611384770696,"['CEBPB', 'ATP2C2']",0.5374511421687308,0,0,2
55,Cytosolic DNA-sensing pathway WP4655,0.1048269108255067,2.7795831021637474,6.269196135455285,"['RNF125', 'IL18', 'IRF7']",0.5374511421687308,0,0,3
56,The alternative pathway of fetal androgen synthesis WP4524,0.10922396591871979,11.393586005830905,25.229441537997488,['HSD17B6'],0.5374511421687308,0,0,1
57,Osteoblast Signaling WP322,0.10922396591871979,11.393586005830905,25.229441537997488,['TNFRSF11B'],0.5374511421687308,0,0,1
58,Robo4 and VEGF Signaling Pathways Crosstalk WP3943,0.10922396591871979,11.393586005830905,25.229441537997488,['VEGFA'],0.5374511421687308,0,0,1
59,IL-18 signaling pathway WP4754,0.11032883495085802,1.7104406980183378,3.7703072645605955,"['ACTA2', 'SOCS3', 'CEBPB', 'IL18', 'FAS', 'HSPB1', 'TNFRSF11B', 'VEGFA']",0.5374511421687308,0,0,8
60,TLR4 Signaling and Tolerance WP3851,0.1193092228269024,3.603570329332102,7.661322573041735,"['IRF7', 'TAB2']",0.5374511421687308,0,0,2
61,Tryptophan metabolism WP465,0.1193092228269024,3.603570329332102,7.661322573041735,"['MAOB', 'HAAO']",0.5374511421687308,0,0,2
62,Intracellular trafficking proteins involved in CMT neuropathy WP4856,0.1193092228269024,3.603570329332102,7.661322573041735,"['HSPB1', 'NDRG1']",0.5374511421687308,0,0,2
63,miRNAs involvement in the immune response in sepsis WP4329,0.1193092228269024,3.603570329332102,7.661322573041735,"['IRF7', 'TAB2']",0.5374511421687308,0,0,2
64,NRF2-ARE regulation WP4357,0.1193092228269024,3.603570329332102,7.661322573041735,"['NQO1', 'CEBPB']",0.5374511421687308,0,0,2
65,IL-4 signaling pathway WP395,0.12324785500553614,2.5704545454545453,5.3813953426431915,"['SOCS3', 'CEBPB', 'IRS2']",0.5374511421687308,0,0,3
66,Aryl Hydrocarbon Receptor Pathway WP2873,0.12887529606809964,3.4230994152046783,7.013622757403326,"['NQO1', 'HES1']",0.5374511421687308,0,0,2
67,Vitamin A and carotenoid metabolism WP716,0.12887529606809964,3.4230994152046783,7.013622757403326,"['RBP2', 'BCO1']",0.5374511421687308,0,0,2
68,Hematopoietic Stem Cell Differentiation WP2849,0.12887529606809964,3.4230994152046783,7.013622757403326,"['HES6', 'TRIM29']",0.5374511421687308,0,0,2
69,Nucleotide-binding Oligomerization Domain (NOD) pathway WP1433,0.12887529606809964,3.4230994152046783,7.013622757403326,"['IL18', 'NOD1']",0.5374511421687308,0,0,2
70,Serotonin Transporter Activity WP1455,0.13461772512811176,8.544460641399416,17.13434519930125,['IL1R1'],0.5374511421687308,0,0,1
71,BMP2-WNT4-FOXO1 pathway in primary endometrial stromal cell differentiation WP3876,0.13461772512811176,8.544460641399416,17.13434519930125,['SMAD9'],0.5374511421687308,0,0,1
72,Estrogen metabolism WP697,0.13461772512811176,8.544460641399416,17.13434519930125,['NQO1'],0.5374511421687308,0,0,1
73,NAD Biosynthesis II (from tryptophan) WP2485,0.13461772512811176,8.544460641399416,17.13434519930125,['HAAO'],0.5374511421687308,0,0,1
74,PTF1A related regulatory pathway WP4147,0.13461772512811176,8.544460641399416,17.13434519930125,['HES1'],0.5374511421687308,0,0,1
75,Oxidation by Cytochrome P450 WP43,0.13861244321518523,3.2598162071846284,6.441636155785306,"['CYP39A1', 'CYP3A7']",0.5374511421687308,0,0,2
76,EGFR Tyrosine Kinase Inhibitor Resistance WP4806,0.13876185403048028,2.078609625668449,4.105245894869905,"['MRAS', 'EGF', 'HGF', 'VEGFA']",0.5374511421687308,0,0,4
77,Interferon type I signaling pathways WP585,0.14274284135827253,2.390506717588488,4.653624718228366,"['SOCS3', 'PDCD4', 'IRS2']",0.5374511421687308,0,0,3
78,Oxysterols derived from cholesterol WP4545,0.1485032217605258,3.111376927166401,5.933858230423861,"['CYP39A1', 'DBP']",0.5374511421687308,0,0,2
79,Regucalcin in proximal tubule epithelial kidney cells WP4838,0.1485032217605258,3.111376927166401,5.933858230423861,"['ACTA2', 'PRKCQ']",0.5374511421687308,0,0,2
80,Osteoblast differentiation WP4787,0.14924299801866808,2.017128027681661,3.8369394666579324,"['HES6', 'WNT7B', 'SMAD9', 'PRKCQ']",0.5374511421687308,0,0,4
81,Senescence and Autophagy in Cancer WP615,0.15459480497962885,1.9877237851662404,3.7109764411246022,"['CEBPB', 'IRF7', 'COL10A1', 'CD44']",0.5374511421687308,0,0,4
82,Somitogenesis in the context of spondylocostal dysostosis WP4785,0.15928961926290375,6.834985422740525,12.556081670595047,['TBX6'],0.5374511421687308,0,0,1
83,Aspirin and miRNAs WP4707,0.15928961926290375,6.834985422740525,12.556081670595047,['VEGFA'],0.5374511421687308,0,0,1
84,Biogenic Amine Synthesis WP550,0.15928961926290375,6.834985422740525,12.556081670595047,['PAH'],0.5374511421687308,0,0,1
85,Urea cycle and related diseases WP4571,0.15928961926290375,6.834985422740525,12.556081670595047,['GLS2'],0.5374511421687308,0,0,1
86,Complement Activation WP545,0.15928961926290375,6.834985422740525,12.556081670595047,['C1R'],0.5374511421687308,0,0,1
87,Farnesoid X receptor pathway WP2879,0.15928961926290375,6.834985422740525,12.556081670595047,['IRS2'],0.5374511421687308,0,0,1
88,Folate-Alcohol and Cancer Pathway Hypotheses WP1589,0.15928961926290375,6.834985422740525,12.556081670595047,['CEBPB'],0.5374511421687308,0,0,1
89,LDLRAD4 and what we know about it WP4904,0.15928961926290375,6.834985422740525,12.556081670595047,['NEDD4'],0.5374511421687308,0,0,1
90,Mammary gland development pathway - Involution (Stage 4 of 4) WP2815,0.15928961926290375,6.834985422740525,12.556081670595047,['SOCS3'],0.5374511421687308,0,0,1
91,"Phase I biotransformations, non P450 WP136",0.15928961926290375,6.834985422740525,12.556081670595047,['PON1'],0.5374511421687308,0,0,1
92,Male infertility WP4673,0.16001781579133734,1.9591596638655462,3.590101546794271,"['NQO1', 'BHMT', 'PON1', 'FAS']",0.5374511421687308,0,0,4
93,Notch Signaling Pathway Netpath WP61,0.1701759148297547,2.186310600861047,3.871786818364567,"['HES6', 'HES1', 'HES5']",0.5654232008859592,0,0,3
94,Methionine metabolism leading to sulfur amino acids and related disorders WP4292,0.1832601095187385,5.69533527696793,9.664122669890313,['BHMT'],0.5909598656448307,0,0,1
95,Osteoclast Signaling WP12,0.1832601095187385,5.69533527696793,9.664122669890313,['TNFRSF11B'],0.5909598656448307,0,0,1
96,Allograft Rejection WP2328,0.18928284248072932,2.631803868645974,4.38067138839127,"['FAS', 'VEGFA']",0.5909598656448307,0,0,2
97,Alpha 6 Beta 4 signaling pathway WP244,0.18928284248072932,2.631803868645974,4.38067138839127,"['IRS2', 'LAMB1']",0.5909598656448307,0,0,2
98,Metapathway biotransformation Phase I and II WP702,0.19392401147956403,1.8035603715170279,2.9583600399428795,"['CYP39A1', 'HS3ST3B1', 'CHST6', 'CYP3A7']",0.5909598656448307,0,0,4
99,Calcium Regulation in the Cardiac Cell WP536,0.20492722325676846,1.6325326590813316,2.5877281241960985,"['RGS17', 'PLN', 'GRK5', 'GJA9', 'PRKCQ']",0.5909598656448307,0,0,5
100,Biomarkers for urea cycle disorders WP4583,0.20654907925450394,4.881299458558934,7.698869576102797,['GLS2'],0.5909598656448307,0,0,1
101,Development and heterogeneity of the ILC family WP3893,0.20654907925450394,4.881299458558934,7.698869576102797,['IL18'],0.5909598656448307,0,0,1
102,Ethanol metabolism resulting in production of ROS by CYP2E1 WP4269,0.20654907925450394,4.881299458558934,7.698869576102797,['PRKCQ'],0.5909598656448307,0,0,1
103,FGF23 signaling in hypophosphatemic rickets and related disorders WP4790,0.20654907925450394,4.881299458558934,7.698869576102797,['FAM20C'],0.5909598656448307,0,0,1
104,Galanin receptor pathway WP4970,0.20654907925450394,4.881299458558934,7.698869576102797,['VEGFA'],0.5909598656448307,0,0,1
105,"GPCRs, Class B Secretin-like WP334",0.20654907925450394,4.881299458558934,7.698869576102797,['CALCRL'],0.5909598656448307,0,0,1
106,Inflammatory Response Pathway WP453,0.20654907925450394,4.881299458558934,7.698869576102797,['LAMB1'],0.5909598656448307,0,0,1
107,Mammary gland development pathway - Puberty (Stage 2 of 4) WP2814,0.20654907925450394,4.881299458558934,7.698869576102797,['EGF'],0.5909598656448307,0,0,1
108,RAS and bradykinin pathways in COVID-19 WP4969,0.20654907925450394,4.881299458558934,7.698869576102797,['SERPING1'],0.5909598656448307,0,0,1
109,Type 2 papillary renal cell carcinoma WP4241,0.21020028205529012,2.4434001670843775,3.810957749850548,"['EGLN3', 'VEGFA']",0.5945516706099356,0,0,2
110,NRF2 pathway WP2884,0.2116526982753816,1.7346239761727476,2.693538964367113,"['NQO1', 'HGF', 'SLC5A3', 'HSPA1A']",0.5945516706099356,0,0,4
111,Parkin-Ubiquitin Proteasomal System pathway WP2359,0.21377511220343087,1.9378077795606705,2.989709321520253,"['RNF19A', 'HSPA1B', 'HSPA1A']",0.5951036907284697,0,0,3
112,15q13.3 copy number variation syndrome WP4942,0.2291758498900797,4.270772594752186,6.291982633981213,['SERPINH1'],0.6157855444872576,0,0,1
113,MFAP5-mediated ovarian cancer cell motility and invasiveness WP3301,0.2291758498900797,4.270772594752186,6.291982633981213,['PRKCQ'],0.6157855444872576,0,0,1
114,Nicotine Activity on Dopaminergic Neurons WP1602,0.2291758498900797,4.270772594752186,6.291982633981213,['CHRNA4'],0.6157855444872576,0,0,1
115,NO metabolism in cystic fibrosis WP4947,0.2291758498900797,4.270772594752186,6.291982633981213,['PRMT8'],0.6157855444872576,0,0,1
116,Hepatitis C and Hepatocellular Carcinoma WP3646,0.23133240330288724,2.2801169590643275,3.3378623669304806,"['CD44', 'VEGFA']",0.6162216605223462,0,0,2
117,T-cell receptor (TCR) signaling pathway WP69,0.23640102411594463,1.8335253456221199,2.644357304151204,"['FAS', 'PRKCQ', 'MAP3K14']",0.6208655346137928,0,0,3
118,Fas ligand pathway and stress induction of heat shock proteins WP314,0.24195051773923984,2.2063761554423693,3.130896406086901,"['HSPB1', 'FAS']",0.6208655346137928,0,0,2
119,Amplification and Expansion of Oncogenic Pathways as Metastatic Traits WP3678,0.2511591968502398,3.795918367346939,5.244700041500307,['VEGFA'],0.6208655346137928,0,0,1
120,Eicosanoid Synthesis WP167,0.2511591968502398,3.795918367346939,5.244700041500307,['PLA2G5'],0.6208655346137928,0,0,1
121,FOXA2 pathway WP5066,0.2511591968502398,3.795918367346939,5.244700041500307,['IRS2'],0.6208655346137928,0,0,1
122,ID signaling pathway WP53,0.2511591968502398,3.795918367346939,5.244700041500307,['ID3'],0.6208655346137928,0,0,1
123,Kynurenine Pathway and links to Cellular Senescence WP5044,0.2511591968502398,3.795918367346939,5.244700041500307,['HAAO'],0.6208655346137928,0,0,1
124,NOTCH1 regulation of endothelial cell calcification WP3413,0.2511591968502398,3.795918367346939,5.244700041500307,['VEGFA'],0.6208655346137928,0,0,1
125,Osteopontin Signaling WP1434,0.2511591968502398,3.795918367346939,5.244700041500307,['MAP3K14'],0.6208655346137928,0,0,1
126,Ebola Virus Pathway on Host WP4217,0.26718823902520356,1.5560160427807486,2.0536328579797805,"['SOCS3', 'ACTN1', 'NEDD4', 'IRF7']",0.6510170611986534,0,0,4
127,Tryptophan catabolism leading to NAD+ production WP4210,0.2725173647217238,3.4160349854227405,4.441026336735217,['HAAO'],0.6510170611986534,0,0,1
128,GPR40 Pathway WP3958,0.2725173647217238,3.4160349854227405,4.441026336735217,['PLCE1'],0.6510170611986534,0,0,1
129,MAPK and NFkB signaling pathways inhibited by Yersinia YopJ WP3849,0.2725173647217238,3.4160349854227405,4.441026336735217,['MAP3K14'],0.6510170611986534,0,0,1
130,Notch Signaling WP268,0.27389067299619724,2.0111799105607155,2.604530789475971,"['HES1', 'HES5']",0.6510170611986534,0,0,2
131,TGF-beta Receptor Signaling WP560,0.28453518376386483,1.9535505430242273,2.455414482097342,"['EGF', 'SMAD9']",0.6575306678313835,0,0,2
132,Cell-type Dependent Selectivity of CCK2R Signaling WP3679,0.2932680823731418,3.105221309302942,3.809076020998021,['CD38'],0.6575306678313835,0,0,1
133,Deregulation of Rab and Rab Effector Genes in Bladder Cancer WP2291,0.2932680823731418,3.105221309302942,3.809076020998021,['SYTL4'],0.6575306678313835,0,0,1
134,Pyrimidine metabolism and related diseases WP4225,0.2932680823731418,3.105221309302942,3.809076020998021,['GLS2'],0.6575306678313835,0,0,1
135,T-Cell antigen Receptor (TCR) pathway during Staphylococcus aureus infection WP3863,0.2951644609636878,1.8991228070175439,2.317352537379013,"['PRKCQ', 'MAP3K14']",0.6575306678313835,0,0,2
136,Glycogen Synthesis and Degradation WP500,0.2951644609636878,1.8991228070175439,2.317352537379013,"['HKDC1', 'GYG2']",0.6575306678313835,0,0,2
137,Circadian rhythm related genes WP3594,0.2957460709619381,1.4029933749214178,1.7092023768481248,"['DBP', 'NOCT', 'ID3', 'FAS', 'CARTPT']",0.6575306678313835,0,0,5
138,Simplified Interaction Map Between LOXL4 and Oxidative Stress Pathway WP3670,0.31342857730189955,2.8462099125364433,3.3021265421641486,['NQO1'],0.6575306678313835,0,0,1
139,Airway smooth muscle cell contraction WP4962,0.31342857730189955,2.8462099125364433,3.3021265421641486,['CD38'],0.6575306678313835,0,0,1
140,Canonical and non-canonical TGF-B signaling WP3874,0.31342857730189955,2.8462099125364433,3.3021265421641486,['LOXL2'],0.6575306678313835,0,0,1
141,Omega-3/Omega-6 FA synthesis WP4723,0.31342857730189955,2.8462099125364433,3.3021265421641486,['PLA2G5'],0.6575306678313835,0,0,1
142,Regulation of apoptosis by parathyroid hormone-related protein WP3872,0.31342857730189955,2.8462099125364433,3.3021265421641486,['BCL2L14'],0.6575306678313835,0,0,1
143,Modulators of TCR signaling and T cell activation WP5072,0.3163467380200799,1.798861188057864,2.0703388332025363,"['PRKCQ', 'MAP3K14']",0.6575306678313835,0,0,2
144,Wnt signaling pathway and pluripotency WP399,0.3218657109113902,1.531054405392393,1.7356352229014338,"['WNT7B', 'PRKCQ', 'CD44']",0.6575306678313835,0,0,3
145,TGF-beta receptor signaling in skeletal dysplasias WP4816,0.3268855601466678,1.752586594691858,1.959646180319789,"['EGF', 'SMAD9']",0.6575306678313835,0,0,2
146,ERK Pathway in Huntington's Disease WP3853,0.3330155898803388,2.6270464229647903,2.8886108578649576,['EGF'],0.6575306678313835,0,0,1
147,Nanomaterial induced apoptosis WP2507,0.3330155898803388,2.6270464229647903,2.8886108578649576,['FAS'],0.6575306678313835,0,0,1
148,Photodynamic therapy-induced NF-kB survival signaling WP3617,0.3330155898803388,2.6270464229647903,2.8886108578649576,['VEGFA'],0.6575306678313835,0,0,1
149,Breast cancer pathway WP4262,0.33795582632438553,1.3818181818181818,1.4990517515906197,"['EGF', 'WNT7B', 'HES1', 'HES5']",0.6575306678313835,0,0,4
150,Glucocorticoid Receptor Pathway WP2880,0.3478262610121557,1.6668092996719441,1.7602375842944369,"['SPINK13', 'SPRY1']",0.6575306678313835,0,0,2
151,Novel intracellular components of RIG-I-like receptor (RLR) pathway WP3865,0.3478262610121557,1.6668092996719441,1.7602375842944369,"['RNF125', 'IRF7']",0.6575306678313835,0,0,2
152,Statin inhibition of cholesterol production WP430,0.35204538703226007,2.439192003331945,2.5465046732633034,['APOC1'],0.6575306678313835,0,0,1
153,Eicosanoid metabolism via cyclooxygenases (COX) WP4719,0.35204538703226007,2.439192003331945,2.5465046732633034,['PLA2G5'],0.6575306678313835,0,0,1
154,Pregnane X receptor pathway WP2876,0.35204538703226007,2.439192003331945,2.5465046732633034,['CYP3A7'],0.6575306678313835,0,0,1
155,Focal Adhesion WP306,0.3577058498945484,1.2857364650564465,1.3217940167641382,"['EGF', 'ACTN1', 'HGF', 'LAMB1', 'VEGFA']",0.6575306678313835,0,0,5
156,RANKL/RANK signaling pathway WP2018,0.3582163938267555,1.626984126984127,1.6702912281554188,"['TNFRSF11B', 'TAB2']",0.6575306678313835,0,0,2
157,EGF/EGFR signaling pathway WP437,0.36338439545954493,1.276031347686347,1.2917189591740745,"['PLSCR1', 'EGF', 'LIMK2', 'NEDD4', 'PLCE1']",0.6575306678313835,0,0,5
158,Insulin Signaling WP481,0.36338439545954493,1.276031347686347,1.2917189591740745,"['SOCS3', 'IRS2', 'PRKCQ', 'MAP3K6', 'MAP3K14']",0.6575306678313835,0,0,5
159,Myometrial relaxation and contraction pathways WP289,0.363974075146315,1.3276984580239863,1.3418685003939572,"['ACTA2', 'RGS17', 'GRK5', 'PRKCQ']",0.6575306678313835,0,0,4
160,ncRNAs involved in Wnt signaling in hepatocellular carcinoma WP4336,0.3685458326694352,1.5890112879096967,1.5861354933406675,"['WIF1', 'WNT7B']",0.6575306678313835,0,0,2
161,G Protein Signaling Pathways WP35,0.36886506939042724,1.404491222432009,1.4007333199620065,"['GNA14', 'PRKCQ', 'PDE8B']",0.6575306678313835,0,0,3
162,Urea cycle and metabolism of amino groups WP497,0.37053377559482503,2.2763848396501456,2.2600191719484926,['ARG2'],0.6575306678313835,0,0,1
163,Photodynamic therapy-induced NFE2L2 (NRF2) survival signaling WP3612,0.37053377559482503,2.2763848396501456,2.2600191719484926,['NQO1'],0.6575306678313835,0,0,1
164,Angiopoietin Like Protein 8 Regulatory Pathway WP3915,0.38346753054403465,1.2897891231964485,1.23626329747528,"['TRIP10', 'IRS2', 'MAP3K6', 'MAP3K14']",0.6575306678313835,0,0,4
165,Sleep regulation WP3591,0.3884961152750192,2.1339285714285716,2.0175699458522343,['IL18'],0.6575306678313835,0,0,1
166,Angiogenesis WP1539,0.3884961152750192,2.1339285714285716,2.0175699458522343,['VEGFA'],0.6575306678313835,0,0,1
167,Canonical and non-canonical Notch signaling WP3845,0.3884961152750192,2.1339285714285716,2.0175699458522343,['HES1'],0.6575306678313835,0,0,1
168,Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells WP4301,0.3884961152750192,2.1339285714285716,2.0175699458522343,['MRAS'],0.6575306678313835,0,0,1
169,Kallmann's Syndrome WP5074,0.3884961152750192,2.1339285714285716,2.0175699458522343,['PRKCQ'],0.6575306678313835,0,0,1
170,Methionine De Novo and Salvage Pathway WP3580,0.3884961152750192,2.1339285714285716,2.0175699458522343,['BHMT'],0.6575306678313835,0,0,1
171,NAD+ biosynthetic pathways WP3645,0.3884961152750192,2.1339285714285716,2.0175699458522343,['CD38'],0.6575306678313835,0,0,1
172,One-carbon metabolism WP241,0.3884961152750192,2.1339285714285716,2.0175699458522343,['BHMT'],0.6575306678313835,0,0,1
173,Cardiac Hypertrophic Response WP2795,0.389003060379734,1.5181286549707602,1.433368599282721,"['EGF', 'MAP3K14']",0.6575306678313835,0,0,2
174,ESC Pluripotency Pathways WP3931,0.3921759527499143,1.348703503627103,1.2624467406042816,"['EGF', 'WNT7B', 'SMAD9']",0.6575306678313835,0,0,3
175,Regulation of toll-like receptor signaling pathway WP1449,0.39990005223657316,1.3310736184636478,1.2199830561777687,"['IRAK2', 'IRF7', 'TAB2']",0.6575306678313835,0,0,3
176,Striated Muscle Contraction Pathway WP383,0.40594733124309523,2.008231864174241,1.8104849953647721,['ACTA2'],0.6575306678313835,0,0,1
177,Type I interferon induction and signaling during SARS-CoV-2 infection WP4868,0.40594733124309523,2.008231864174241,1.8104849953647721,['IRF7'],0.6575306678313835,0,0,1
178,Urea cycle and associated pathways WP4595,0.40594733124309523,2.008231864174241,1.8104849953647721,['GLS2'],0.6575306678313835,0,0,1
179,Ebstein-Barr virus LMP1 signaling WP262,0.40594733124309523,2.008231864174241,1.8104849953647721,['MAP3K14'],0.6575306678313835,0,0,1
180,FBXL10 enhancement of MAP/ERK signaling in diffuse large B-cell lymphoma WP4553,0.40594733124309523,2.008231864174241,1.8104849953647721,['BCL6'],0.6575306678313835,0,0,1
181,Gastric Cancer Network 2 WP2363,0.40594733124309523,2.008231864174241,1.8104849953647721,['S100A6'],0.6575306678313835,0,0,1
182,Genes controlling nephrogenesis WP4823,0.40594733124309523,2.008231864174241,1.8104849953647721,['VEGFA'],0.6575306678313835,0,0,1
183,Hematopoietic Stem Cell Gene Regulation by GABP alpha/beta Complex WP3657,0.40594733124309523,2.008231864174241,1.8104849953647721,['ETV6'],0.6575306678313835,0,0,1
184,Metabolism of Spingolipids in ER and Golgi apparatus WP4142,0.40594733124309523,2.008231864174241,1.8104849953647721,['UGCG'],0.6575306678313835,0,0,1
185,Prostaglandin Synthesis and Regulation WP98,0.40594733124309523,2.008231864174241,1.8104849953647721,['S100A6'],0.6575306678313835,0,0,1
186,p53 transcriptional gene network WP4963,0.4091620314456767,1.453278586537265,1.2987137422148478,"['GLS2', 'FAS']",0.6575306678313835,0,0,2
187,Regulatory circuits of the STAT3 signaling pathway WP4538,0.4091620314456767,1.453278586537265,1.2987137422148478,"['SOCS3', 'OSMR']",0.6575306678313835,0,0,2
188,7-oxo-C and 7beta-HC pathways WP5064,0.42290192644179797,1.8965014577259476,1.632157562595927,['DBP'],0.6575306678313835,0,0,1
189,Vitamin D in inflammatory diseases WP4482,0.42290192644179797,1.8965014577259476,1.632157562595927,['DUSP1'],0.6575306678313835,0,0,1
190,Wnt/beta-catenin signaling pathway in leukemia WP3658,0.42290192644179797,1.8965014577259476,1.632157562595927,['WIF1'],0.6575306678313835,0,0,1
191,Fibrin Complement Receptor 3 Signaling Pathway WP4136,0.42290192644179797,1.8965014577259476,1.632157562595927,['IRAK2'],0.6575306678313835,0,0,1
192,Hereditary leiomyomatosis and renal cell carcinoma pathway WP4206,0.42290192644179797,1.8965014577259476,1.632157562595927,['VEGFA'],0.6575306678313835,0,0,1
193,Hippo-Yap signaling pathway WP4537,0.42290192644179797,1.8965014577259476,1.632157562595927,['NDRG1'],0.6575306678313835,0,0,1
194,PKC-gamma calcium signaling pathway in ataxia WP4760,0.42290192644179797,1.8965014577259476,1.632157562595927,['GNA14'],0.6575306678313835,0,0,1
195,Integrated breast cancer pathway WP1984,0.4349961678936591,1.1984520123839009,0.9976130960023153,"['BARD1', 'ITPKC', 'RASGEF1A', 'VEGFA']",0.6575306678313835,0,0,4
196,Sphingolipid Metabolism (general overview) WP4725,0.4393739935183431,1.7965321466932638,1.4774757753416292,['UGCG'],0.6575306678313835,0,0,1
197,Toll-like Receptor Signaling related to MyD88 WP3858,0.4393739935183431,1.7965321466932638,1.4774757753416292,['IRF7'],0.6575306678313835,0,0,1
198,Unfolded protein response WP4925,0.4393739935183431,1.7965321466932638,1.4774757753416292,['TXNIP'],0.6575306678313835,0,0,1
199,Vitamin B12 metabolism WP1533,0.4393739935183431,1.7965321466932638,1.4774757753416292,['SERPINA3'],0.6575306678313835,0,0,1
200,Endothelin Pathways WP2197,0.4393739935183431,1.7965321466932638,1.4774757753416292,['CALCRL'],0.6575306678313835,0,0,1
201,Extracellular vesicle-mediated signaling in recipient cells WP2870,0.4393739935183431,1.7965321466932638,1.4774757753416292,['HGF'],0.6575306678313835,0,0,1
202,Gastrin signaling pathway WP4659,0.44559348264037435,1.234215454192135,0.9976758611822066,"['PRKCQ', 'CD44', 'VEGFA']",0.6575306678313835,0,0,3
203,Apoptosis WP254,0.4484653222280067,1.3388372893016856,1.0736456471713653,"['IRF7', 'FAS']",0.6575306678313835,0,0,2
204,MET in type 1 papillary renal cell carcinoma WP4205,0.4484653222280067,1.3388372893016856,1.0736456471713653,"['HGF', 'ETS1']",0.6575306678313835,0,0,2
205,Sphingolipid Metabolism (integrated pathway) WP4726,0.4553772262651005,1.7065597667638484,1.3424296328212908,['UGCG'],0.6575306678313835,0,0,1
206,Trans-sulfuration and one-carbon metabolism WP2525,0.4553772262651005,1.7065597667638484,1.3424296328212908,['BHMT'],0.6575306678313835,0,0,1
207,Cell migration and invasion through p75NTR WP4561,0.4553772262651005,1.7065597667638484,1.3424296328212908,['EFNB3'],0.6575306678313835,0,0,1
208,Type II interferon signaling (IFNG) WP619,0.4553772262651005,1.7065597667638484,1.3424296328212908,['SOCS3'],0.6575306678313835,0,0,1
209,Wnt signaling in kidney disease WP4150,0.4553772262651005,1.7065597667638484,1.3424296328212908,['WNT7B'],0.6575306678313835,0,0,1
210,EPO Receptor Signaling WP581,0.4553772262651005,1.7065597667638484,1.3424296328212908,['IRS2'],0.6575306678313835,0,0,1
211,Heart Development WP1591,0.4553772262651005,1.7065597667638484,1.3424296328212908,['VEGFA'],0.6575306678313835,0,0,1
212,Oxidative Stress WP408,0.4553772262651005,1.7065597667638484,1.3424296328212908,['NQO1'],0.6575306678313835,0,0,1
213,Pre-implantation embryo WP3527,0.4553772262651005,1.7065597667638484,1.3424296328212908,['ZFP36'],0.6575306678313835,0,0,1
214,SARS-CoV-2 mitochondrial interactions WP5038,0.4553772262651005,1.7065597667638484,1.3424296328212908,['IRF7'],0.6575306678313835,0,0,1
215,LncRNA involvement in canonical Wnt signaling and colorectal cancer WP4258,0.4580614267862019,1.3129779577147997,1.0251101457500742,"['WIF1', 'WNT7B']",0.6583301436136576,0,0,2
216,Focal Adhesion-PI3K-Akt-mTOR-signaling pathway WP3932,0.46799778817417964,1.101450658522619,0.8363223531082307,"['EGF', 'HGF', 'IRS2', 'LAMB1', 'OSMR', 'VEGFA']",0.6694968358602847,0,0,6
217,Overview of leukocyte-intrinsic Hippo pathway functions WP4542,0.47092493105034455,1.6251561849229488,1.2238345581404277,['NDRG1'],0.6705797405279099,0,0,1
218,Toll-like Receptor Signaling Pathway WP75,0.4769597835411968,1.2641325536062378,0.9358665345406444,"['IRF7', 'TAB2']",0.6760576748359166,0,0,2
219,MTHFR deficiency WP4288,0.4860300375810509,1.5511529287039492,1.1191333400617702,['BHMT'],0.6829710658538949,0,0,1
220,MECP2 and Associated Rett Syndrome WP3584,0.48625771678918084,1.2410419989367358,0.8948117760143559,"['CEBPD', 'BCL6']",0.6829710658538949,0,0,2
221,16p11.2 distal deletion syndrome WP4950,0.5007051096694813,1.4835847382431233,1.0262518723769412,['PLN'],0.6907048164637042,0,0,1
222,Sphingolipid pathway WP1422,0.5007051096694813,1.4835847382431233,1.0262518723769412,['UGCG'],0.6907048164637042,0,0,1
223,Neovascularisation processes WP4331,0.5007051096694813,1.4835847382431233,1.0262518723769412,['SMAD9'],0.6907048164637042,0,0,1
224,Photodynamic therapy-induced HIF-1 survival signaling WP3614,0.5007051096694813,1.4835847382431233,1.0262518723769412,['VEGFA'],0.6907048164637042,0,0,1
225,Resistin as a regulator of inflammation WP4481,0.5149623554274794,1.4216472303206997,0.9434925009992877,['PLCE1'],0.7051918281653279,0,0,1
226,Ras signaling WP4223,0.5157713694671977,1.0745715609078277,0.7114649052130353,"['MRAS', 'PLCE1', 'PLA2G5', 'ETS1']",0.7051918281653279,0,0,4
227,Kisspeptin/kisspeptin receptor system in the ovary WP4871,0.5288136374564913,1.3646647230320699,0.8694540984296485,['PRKCQ'],0.71355202608758,0,0,1
228,Oxidative Damage WP3941,0.5288136374564913,1.3646647230320699,0.8694540984296485,['C1R'],0.71355202608758,0,0,1
229,Proximal tubule transport WP4917,0.5288136374564913,1.3646647230320699,0.8694540984296485,['SLC3A1'],0.71355202608758,0,0,1
230,Prolactin Signaling Pathway WP2037,0.5311659648526976,1.1371345029239766,0.7194431159176475,"['SOCS3', 'IRS2']",0.7136099266934068,0,0,2
231,DNA IR-damage and cellular response via ATR WP4016,0.5398220210277451,1.1183970856102003,0.6895094565505241,"['BARD1', 'BCL6']",0.7220995865695811,0,0,2
232,Intraflagellar transport proteins binding to dynein WP4532,0.5422704825296107,1.3120654855348732,0.8029714245936006,['IFT27'],0.7222481857829729,0,0,1
233,Folate Metabolism WP176,0.5553440909319325,1.2633624878522838,0.7430685964922678,['SERPINA3'],0.7364863695191722,0,0,1
234,MicroRNAs in cardiomyocyte hypertrophy WP1544,0.5651220439336339,1.0656980994152048,0.6082083606780521,"['EGF', 'MAP3K14']",0.7437542876961978,0,0,2
235,VEGFA-VEGFR2 Signaling Pathway WP3888,0.5678506681374491,0.981897875718304,0.5556528687769494,"['HSPB1', 'TXNIP', 'FAS', 'NRARP', 'PLA2G5', 'NDRG1', 'ETS1', 'APOLD1', 'HSPA1A', 'VEGFA']",0.7437542876961978,0,0,10
236,Development of ureteric collection system WP5053,0.568045345942727,1.2181382757184507,0.6889230097620804,['SPRY1'],0.7437542876961978,0,0,1
237,Amino Acid metabolism WP3925,0.5733306816834135,1.049212775528565,0.5836693267994792,"['ARG2', 'BHMT']",0.7475070913087544,0,0,2
238,Corticotropin-releasing hormone signaling pathway WP2355,0.5814262809209926,1.0332270069112175,0.5602891342803272,"['IL18', 'PRKCQ']",0.7532641734197194,0,0,2
239,TGF-beta Signaling Pathway WP366,0.5857247981707957,0.99285368561911,0.5310826264905851,"['KLF6', 'LIMK2', 'ETS1']",0.7532641734197194,0,0,3
240,B Cell Receptor Signaling Pathway WP23,0.5894086000860389,1.0177184254167757,0.53800220829126,"['BCL6', 'ETS1']",0.7532641734197194,0,0,2
241,Signaling of Hepatocyte Growth Factor Receptor WP313,0.592372796572789,1.136734693877551,0.5952160182066227,['HGF'],0.7532641734197194,0,0,1
242,TNF related weak inducer of apoptosis (TWEAK) Signaling Pathway WP2036,0.592372796572789,1.136734693877551,0.5952160182066227,['MAP3K14'],0.7532641734197194,0,0,1
243,Photodynamic therapy-induced AP-1 survival signaling. WP3611,0.592372796572789,1.136734693877551,0.5952160182066227,['FAS'],0.7532641734197194,0,0,1
244,Pathways in clear cell renal cell carcinoma WP4018,0.5972775030433006,1.0026659786721706,0.5167474189818066,"['ENPP3', 'VEGFA']",0.7563883132802455,0,0,2
245,Host-pathogen interaction of human coronaviruses - MAPK signaling WP4877,0.6040192522533832,1.0999717859494027,0.5545499035687395,['IFITM3'],0.7587071095377862,0,0,1
246,p38 MAPK Signaling Pathway WP400,0.6040192522533832,1.0999717859494027,0.5545499035687395,['HSPB1'],0.7587071095377862,0,0,1
247,Ferroptosis WP4313,0.6153338914659594,1.065506559766764,0.5173995919888227,['CP'],0.7596524625016718,0,0,1
248,IL-2 signaling pathway WP49,0.6153338914659594,1.065506559766764,0.5173995919888227,['SOCS3'],0.7596524625016718,0,0,1
249,Integrated Cancer Pathway WP1971,0.6153338914659594,1.065506559766764,0.5173995919888227,['BARD1'],0.7596524625016718,0,0,1
250,Phosphoinositides metabolism WP4971,0.6153338914659594,1.065506559766764,0.5173995919888227,['PLCE1'],0.7596524625016718,0,0,1
251,Regulation of Actin Cytoskeleton WP51,0.617063974394562,0.9464809384164223,0.45694450391487895,"['MRAS', 'EGF', 'ACTN1']",0.7596524625016718,0,0,3
252,Pancreatic adenocarcinoma pathway WP4263,0.620203810651513,0.9600527139444857,0.4586240248074052,"['EGF', 'VEGFA']",0.7604880059179266,0,0,2
253,Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms WP4534,0.6263261411877824,1.0331301351709514,0.4833851131005315,['ACTA2'],0.7605272723364932,0,0,1
254,Nephrotic syndrome WP4758,0.6263261411877824,1.0331301351709514,0.4833851131005315,['PLCE1'],0.7605272723364932,0,0,1
255,22q11.2 copy number variation syndrome WP4657,0.6276195936757468,0.9466374269005848,0.440963629380839,"['ACTA2', 'HES1']",0.7605272723364932,0,0,2
256,TNF-alpha signaling pathway WP231,0.6349226640195247,0.9335896819674757,0.424085051587843,"['TAB2', 'MAP3K14']",0.7629247859802636,0,0,2
257,Wnt signaling WP428,0.6349226640195247,0.9335896819674757,0.424085051587843,"['WIF1', 'WNT7B']",0.7629247859802636,0,0,2
258,SARS-CoV-2 innate immunity evasion and cell-specific immune response WP5039,0.6370051611097347,1.0026582061395988,0.45217631244546597,['IRF7'],0.7629247859802636,0,0,1
259,Hepatitis B infection WP4666,0.646765495217908,0.9042119741520256,0.39402980794450415,"['IRF7', 'FAS', 'TAB2']",0.7639558277905952,0,0,3
260,Hedgehog Signaling Pathway WP4249,0.6473798516596683,0.9739275301957517,0.4234851748815019,['BOC'],0.7639558277905952,0,0,1
261,IL-6 signaling pathway WP364,0.6473798516596683,0.9739275301957517,0.4234851748815019,['SOCS3'],0.7639558277905952,0,0,1
262,PI3K-Akt signaling pathway WP4172,0.6477554267997928,0.9052752149626562,0.39310859381311974,"['EGF', 'HGF', 'LAMB1', 'OSMR', 'VEGFA']",0.7639558277905952,0,0,5
263,Interleukin-11 Signaling Pathway WP2332,0.6574588610624634,0.9467930029154519,0.39705950307041044,['SOCS3'],0.7724516656589399,0,0,1
264,DNA damage response (only ATM dependent) WP710,0.6630164803373175,0.88478772689299,0.3636083224314315,"['BCL6', 'WNT7B']",0.7751144099025115,0,0,2
265,IL-3 signaling pathway WP286,0.6672505923432623,0.9211252068394925,0.37267768171143084,['ENPP3'],0.7751144099025115,0,0,1
266,One-carbon metabolism and related pathways WP3940,0.6672505923432623,0.9211252068394925,0.37267768171143084,['BHMT'],0.7751144099025115,0,0,1
267,ATM Signaling Network in Development and Disease  WP3878,0.6767632104621252,0.89680834739911,0.35014431805889645,['HSPB1'],0.7802978807193907,0,0,1
268,Phosphodiesterases in neuronal function WP4222,0.6767632104621252,0.89680834739911,0.35014431805889645,['PDE8B'],0.7802978807193907,0,0,1
269,Translation inhibitors in chronically activated PDGFRA cells WP4566,0.6860046489658831,0.8737385063915676,0.3292865948666801,['PDCD4'],0.7880127752061631,0,0,1
270,Envelope proteins and their potential roles in EDMD physiopathology WP4535,0.6949826166832785,0.8518221574344024,0.3099512044356274,['SYNE2'],0.7907095140647924,0,0,1
271,Neurodegeneration with brain iron accumulation (NBIA) subtypes pathway WP4577,0.6949826166832785,0.8518221574344024,0.3099512044356274,['CP'],0.7907095140647924,0,0,1
272,Nonalcoholic fatty liver disease WP4396,0.6960290868143156,0.8368588048651507,0.3032473601277636,"['SOCS3', 'FAS', 'IRS2']",0.7907095140647924,0,0,3
273,Synaptic Vesicle Pathway WP2267,0.7121778879114042,0.8111203665139525,0.27531660379265505,['SLC22A3'],0.8060914555480729,0,0,1
274,Selenium Micronutrient Network WP15,0.7204095407424019,0.7921893009695573,0.2597869327922108,['SERPINA3'],0.8124326572605919,0,0,1
275,Arrhythmogenic Right Ventricular Cardiomyopathy WP2118,0.7510543706244436,0.7245208113640593,0.2074138125506595,['ACTN1'],0.8378187744510942,0,0,1
276,DNA damage response WP707,0.7510543706244436,0.7245208113640593,0.2074138125506595,['FAS'],0.8378187744510942,0,0,1
277,Rett syndrome causing genes WP4312,0.7510543706244436,0.7245208113640593,0.2074138125506595,['SYNE2'],0.8378187744510942,0,0,1
278,AGE/RAGE pathway WP2324,0.7581771176773666,0.709365889212828,0.1963796157441331,['LGALS3'],0.8427220480658499,0,0,1
279,miRNA regulation of DNA damage response WP1530,0.7650966450843121,0.6948295353126673,0.1860427757337296,['FAS'],0.8473651015449907,0,0,1
280,Primary focal segmental glomerulosclerosis (FSGS) WP2572,0.7718187344275631,0.6808746355685131,0.17635031388635955,['PLCE1'],0.8504073401615196,0,0,1
281,Mesodermal commitment pathway WP2857,0.7733477753572396,0.7085160818713451,0.18210735779843082,"['HMGA2', 'TBX6']",0.8504073401615196,0,0,2
282,3q29 copy number variation syndrome WP4906,0.7846929102104724,0.6545750168199148,0.15871011424689285,['PIGM'],0.8598230824646665,0,0,1
283,Melanoma WP4685,0.8083087511083062,0.6076114119117034,0.1293064989626519,['ETS1'],0.8792427004866137,0,0,1
284,Ectoderm Differentiation WP2858,0.8095142110199728,0.6535650022492128,0.13811197762793595,"['BOC', 'TNFRSF11B']",0.8792427004866137,0,0,2
285,Endometrial cancer WP4155,0.8137974509358301,0.5969004143010588,0.12298761508994438,['EGF'],0.8792427004866137,0,0,1
286,Proteasome Degradation WP183,0.8137974509358301,0.5969004143010588,0.12298761508994438,['NEDD4'],0.8792427004866137,0,0,1
287,Head and Neck Squamous Cell Carcinoma WP4674,0.819129434778792,0.5865587614356087,0.11702619647352219,['VEGFA'],0.8819198444134032,0,0,1
288,Retinoblastoma gene in cancer WP2446,0.8293409757748577,0.5669096209912536,0.10608233847399727,['BARD1'],0.8888854684079313,0,0,1
289,16p11.2 proximal deletion syndrome WP4949,0.834229080382848,0.5575682263537733,0.10105770081246981,['TBX6'],0.8888854684079313,0,0,1
290,Non-small cell lung cancer WP4255,0.834229080382848,0.5575682263537733,0.10105770081246981,['EGF'],0.8888854684079313,0,0,1
291,Thyroid hormones production and their peripheral downstream signaling effects WP4746,0.8389775709472733,0.5485281670271795,0.09630580663565366,['PRKCQ'],0.890873090799682,0,0,1
292,Alzheimer's disease WP2059,0.8435904238879866,0.5397750937109538,0.09180936433827437,['FAS'],0.8927035650047528,0,0,1
293,Leptin signaling pathway WP2034,0.8524245608408743,0.5230769230769231,0.08351998806707228,['SOCS3'],0.8989733423202393,0,0,1
294,Pathways Regulating Hippo Signaling WP4540,0.8566532456092868,0.5151073416379539,0.0796984672101103,['PRKCQ'],0.9003600438546585,0,0,1
295,Glioblastoma signaling pathways WP2261,0.8607611003495722,0.5073756581523867,0.07607503385750686,['PRKCQ'],0.9016107796881959,0,0,1
296,Small cell lung cancer WP4658,0.8686279932014958,0.4925846114843453,0.06937577994664204,['LAMB1'],0.9037240737348895,0,0,1
297,Hippo-Merlin Signaling Dysregulation WP4541,0.8686279932014958,0.4925846114843453,0.06937577994664204,['CD44'],0.9037240737348895,0,0,1
298,Pyrimidine metabolism WP4022,0.8760516245831813,0.47862686322013714,0.06333681610879384,['ENPP3'],0.9083891006583993,0,0,1
299,Androgen receptor signaling pathway WP138,0.8928314701117179,0.4469464477520331,0.0506647047745922,['LIMK2'],0.9226920543963908,0,0,1
300,ErbB signaling pathway WP673,0.8988908598042016,0.43541152724826193,0.04641210553306582,['EGF'],0.9258575855983276,0,0,1
301,7q11.23 copy number variation syndrome WP4932,0.9073453595482491,0.4191771946873988,0.04075749151411649,['FAS'],0.9314608508319235,0,0,1
302,Cytoplasmic Ribosomal Proteins WP477,0.9175315177929135,0.3993140113188132,0.03436829721779624,['RPS4Y1'],0.9387988046291731,0,0,1
303,Ciliary landscape WP4352,0.9246392065458788,0.5202797202797202,0.0407647821078495,"['CDH23', 'IFT27', 'MAPRE2']",0.9429488938042131,0,0,3
304,Ciliopathies WP4803,0.935348392584909,0.44831726114403003,0.029963825135658824,"['IFT27', 'PKD1L1']",0.9479994363773576,0,0,2
305,Epithelial to mesenchymal transition in colorectal cancer WP4239,0.936551281282334,0.3608026797345078,0.02365097651472729,['WNT7B'],0.9479994363773576,0,0,1
306,Chemokine signaling pathway WP3929,0.9418635176953035,0.3495536653542124,0.020936482032539117,['GRK5'],0.9479994363773576,0,0,1
307,Genes related to primary cilium development (based on CRISPR) WP4536,0.9418635176953035,0.3495536653542124,0.020936482032539117,['IFT27'],0.9479994363773576,0,0,1
308,mRNA Processing WP411,0.9727765933680773,0.275047998293394,0.007591552809874509,['U2AF1'],0.9750611203943278,0,0,1
309,Brain-derived neurotrophic factor (BDNF) signaling pathway WP2380,0.9750611203943278,0.26842982090795503,0.006779227973485277,['IRS2'],0.9750611203943278,0,0,1
